sun pharma q2 results 2024

Sun Pharma Q2 Results, Profit Grows by 28%: Sun Pharma Share Price Slides

Sun Pharma Q2 Results FY25 reported a 28% year-on-year growth in the consolidated net profit. On the Sun Pharma Q2 results date which was October 28, 2024, the Sun Pharma share price closed at ₹1,902.90. On October 29, 2024, Sun Pharma share price closed with a fall at ₹1,871.60. So, let’s get into the details of the pharma player’s Q2 FY25 revenue and segment earnings.

Sun Pharma Q2 Results FY25: Profit and Revenue

Sun Pharma share price has delivered negative returns of 1.65% in the last 1 day (as on October 29, 2024) amidst a rise in profits. The consolidated net profit was ₹3,040 crores in the second quarter of FY25 higher than the net profit of ₹2,375 crores in the sequential quarter of FY24.

The revenue from operations rose to ₹13,291 crores in Q2 FY25 with a growth of 9% YoY. The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) was ₹3,939 crores, showing a growth of 24% YoY, while the EBITDA margin was 29.6% in Q2 FY25.

Sun Pharma Q2 Results: Segment Performance

The sale of formulations in India rose by 11% YoY to ₹4,265 crores which constitutes 32% of the overall sales in Q2 FY25. The US formulations sales which constitute 33% of the total sales rose by 20% YoY to $517 million in the second quarter of FY25.

The sales in the emerging markets were at $293 million for the September quarter, up by 3% YoY. The sales of formulations in the rest of the world fell by 3% YoY to $199 million in Q2 FY25. In API (Active Pharmaceutical Ingredient), external sales grew by 7% YoY to ₹534 crores in Q2 FY25.

Conclusion

Sun Pharma Q2 results for FY25 highlighted that the company is focusing on increasing API supply. With a strong R&D expenditure, the company had entered into an agreement with Philogen to commercialize late-stage candidate Fibromun. Fibromun will help the company to expand its product portfolio for dermatologists. In the last 1-year, Sun Pharma share price has delivered a return of 68.42% (as on October 29, 2024).

Keep exploring stocks and open demat account with SMC Global Securities. Stay tuned for the upcoming Nifty 50 companies quarterly results.

Reference

https://sunpharma.com/wp-content/uploads/2024/10/Press-Release-Sun-Pharma-Q2FY25-Financial-Result.pdf

Author: All Content is verified by SMC Global Securities.

WHY SMC

  • 20 Lac+ unique clients
  • 33+ Years of Serving
  • Advance Technical Analysis
  • Free Demat Account


Swiggy IPO 2024, Financials, Date, Share Price Afcons Infrastructure IPO Opening, Listing Date, and Financials Waaree Energies IPO Details, Financials, Peers Freshara Agro Exports IPO Date, Financials, Listing Lakshya Powertech IPO, Bidding Date, Financials Hyundai Motor India IPO Details Shiv Texchem IPO: Date, Financials, Peers Garuda Construction and Engineering IPO Important Dates and Details Khyati Global Ventures IPO Important Dates and Details Intraday Trading Strategies: Achieving Consistent Success
Open Free Demat Account